Recombinant Anti-HER1 x Anti-HER3 Bispecific Antibody (Tandem Diabody) (T-BSDB-165)

Recombinant Anti-HER1 x Anti-HER3 Bispecific Antibody (Tandem Diabody) is designed to be expressed as a monomeric subunit (single chain Diabody, scDb), with four variable domains from two parental antibodies. Then the two peptide chains can dimerize in a head-to-tail fashion. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Head and neck cancer; Colorectal cancer therapy.

Datasheet INQUIRY

Specifications

Targets

HER1 & HER3

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Head and neck cancer; Colorectal cancer

Targets

Target 1

HER1

Gene ID

1956

UniProt ID

P00533

Alternative Names

EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

Target 2

HER3

Gene ID

2065

UniProt ID

P21860

Alternative Names

ERBB3; erb-b2 receptor tyrosine kinase 3; HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; receptor tyrosine-protein kinase erbB-3; proto-oncogene-like protein c-ErbB-3; human epidermal growth factor receptor 3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-HER1 x Anti-HER3 Bispecific Antibody (Tandem Diabody) (T-BSDB-165). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-HER1 x Anti-HER3 Bispecific Antibody (Tandem Diabody) (CAT#: T-BSDB-165)

Specifications

Targets

Customer Reviews and Q&As